Press

B.C. heart device firm Kardium founded by Creo executives raises $115-million from Fidelity, T. Rowe Price ahead of going public

01/25/2021

Kardium's Globe Mapping and Ablation System is intended to disrupt a roughly $6-billion market for treating atrial fibrillation, which is expected to grow by 15 per cent a year as Baby Boomers age.

Read More

B.C. companies seeking new markets take advantage of favourable travel policies (BIV)

09/30/2020

The EU’s favourable polic, is creating advantages for Canadian firms like Kardium looking to expand globally amid the pandemic.

Read More

Kardium completes first commercial procedures with the Globe Mapping and Ablation System

09/11/2020

Early successes in roll-out of world’s most complete solution for atrial fibrillation

Read More

Commercialization prospects appear fruitful for BC’s Kardium even amid pandemic (Business in Vancouver)

06/30/2020

Medical device company gets certification for European sales.

Read More

Kardium® announces successful results from the GLOBAL-AF study (Financial Post)

10/08/2019

Global-AF study demonstrated a 76% percent freedom from atrial fibrillation at 12 months after a single treatment with the Globe System.

Read More

Kardium Announces New Financing to Commercialize the Globe System for the Treatment of Atrial Fibrillation (Cardiac Vascular News)

02/07/2019

Financing was led by funds and accounts advised by T. Rowe Price Associates, Inc., and included participation from other new and existing Kardium shareholders.

Read More

Kardium seeking CE Mark for breakthrough treatment of atrial fibrillation (BioTuesdays)

06/26/2018

Kardium hopes to receive marketing approval in Europe and launch its breakthrough Globe Mapping and Ablation System.

Read More

European fortunes in forecast for B.C. pharma (Business in Vancouver)

04/26/2018

Burnaby-based medical technology maker Kardium Inc. is launching a device to treat atrial fibrillation in Europe.

Read More